By Jill Redhage
Daily Journal Staff Writer
Mountain View-based Fenwick & West reported good news for venture capital-backed technology and life sciences companies in Silicon Valley: 55 percent of the financing rounds conducted during the second quarter of 2010 valued these companies at a higher price per share than their previous financing rounds did.
"The good news is that the amount of dollars that venture capitalists invested last quarter was up, ...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In